Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, VidyaVihar, Raebareily Road, Lucknow, 226025, India.
Department of Pharmaceutical Sciences, Assam University, Silchar, Assam, 788011, India.
BMC Mol Cell Biol. 2021 Jun 5;22(1):33. doi: 10.1186/s12860-021-00371-9.
In the present study, fatty acid synthesis is targeted to combat mammary gland carcinoma by activating prolyl hydroxylase-2 with Voacamine alone and in combination with Tamoxifen. It was hypothesized that the activation of prolyl hydroxylase-2 would inhibit the hypoxia-induced fatty acid synthesis and mammary gland carcinoma. Mammary gland carcinoma was induced with a single dose administration of N-methyl-N-nitrosourea (50 mg/kg,i.p.) and treatment with Voacamine and Tamoxifen 15 days after carcinogen administration.
At the end of the study, hemodynamic profiling of animals was recorded to assess the cardiotoxic potential of the drug. Blood serum was separated and subjected to nuclear magnetic resonance spectroscopy. Carmine staining and histopathology of mammary gland tissue were performed to evaluate the anti-angiogenic potential of the drug. The antioxidant potential of the drug was measured with antioxidant markers. Western blotting was performed to study the effect of the drug at the molecular level.
Results of the study have shown that Voacamine treatment stopped further decrease in body weight of experimental animals. The hemodynamic study evidenced that Voacamine at a low dose is safe in cardiac patients. Microscopic evaluation of mammary gland tissue documented the anti-angiogenic potential of Voacamine and Tamoxifen therapy. Perturbed serum metabolites were also restored to normal along with antioxidant markers. Immunoblotting of mammary gland tissue also depicted restoration of proteins of the hypoxic and fatty acid pathway. Conclusively, Voacamine and its combination with Tamoxifen activated prolyl hydroxylase-2 to combat mammary gland carcinoma.
在本研究中,通过单独使用香草酸胺和联合使用他莫昔芬激活脯氨酰羟化酶-2来靶向脂肪酸合成以治疗乳腺癌。假设激活脯氨酰羟化酶-2将抑制缺氧诱导的脂肪酸合成和乳腺癌。在致癌物给药后 15 天,通过单次给予 N-甲基-N-亚硝基脲(50mg/kg,ip)诱导乳腺癌,并给予香草酸胺和他莫昔芬进行治疗。
在研究结束时,记录动物的血液动力学特征以评估药物的心脏毒性潜力。分离血清并进行核磁共振波谱分析。对乳腺组织进行胭脂红染色和组织病理学检查,以评估药物的抗血管生成潜力。使用抗氧化标记物测量药物的抗氧化潜力。进行 Western 印迹以研究药物在分子水平上的作用。
研究结果表明,香草酸胺治疗阻止了实验动物体重进一步下降。血流动力学研究证明,低剂量的香草酸胺在心脏病患者中是安全的。乳腺组织的显微镜评估证明了香草酸胺和他莫昔芬治疗的抗血管生成潜力。受损的血清代谢物也与抗氧化标记物一起恢复正常。乳腺组织的免疫印迹也描绘了缺氧和脂肪酸途径的蛋白质的恢复。总之,香草酸胺及其与他莫昔芬的联合使用激活了脯氨酰羟化酶-2 来治疗乳腺癌。